vs
Side-by-side financial comparison of EGAIN Corp (EGAN) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $23.0M, roughly 1.2× EGAIN Corp). EGAIN Corp runs the higher net margin — 10.2% vs -147.1%, a 157.3% gap on every dollar of revenue. On growth, EGAIN Corp posted the faster year-over-year revenue change (2.6% vs -67.6%).
Headquartered in Sunnyvale, California, eGain Corporation helps businesses automate customer and employee experience with its AI knowledge software.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
EGAN vs SPRY — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $28.1M |
| Net Profit | $2.3M | $-41.3M |
| Gross Margin | 73.1% | — |
| Operating Margin | 8.9% | -147.6% |
| Net Margin | 10.2% | -147.1% |
| Revenue YoY | 2.6% | -67.6% |
| Net Profit YoY | 248.1% | -182.8% |
| EPS (diluted) | $0.08 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $28.1M | ||
| Q3 25 | $23.5M | $32.5M | ||
| Q2 25 | $23.2M | $15.7M | ||
| Q1 25 | $21.0M | $8.0M | ||
| Q4 24 | $22.4M | $86.6M | ||
| Q3 24 | $21.8M | $2.1M | ||
| Q2 24 | $22.5M | $500.0K | ||
| Q1 24 | $22.4M | $0 |
| Q4 25 | $2.3M | $-41.3M | ||
| Q3 25 | $2.8M | $-51.2M | ||
| Q2 25 | $30.9M | $-44.9M | ||
| Q1 25 | $66.0K | $-33.9M | ||
| Q4 24 | $671.0K | $49.9M | ||
| Q3 24 | $652.0K | $-19.1M | ||
| Q2 24 | $1.5M | $-12.5M | ||
| Q1 24 | $1.5M | $-10.3M |
| Q4 25 | 73.1% | — | ||
| Q3 25 | 75.2% | — | ||
| Q2 25 | 72.7% | — | ||
| Q1 25 | 68.0% | — | ||
| Q4 24 | 70.2% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.3% | — | ||
| Q1 24 | 69.3% | — |
| Q4 25 | 8.9% | -147.6% | ||
| Q3 25 | 12.1% | -163.7% | ||
| Q2 25 | 14.0% | -302.9% | ||
| Q1 25 | 0.1% | -466.3% | ||
| Q4 24 | 2.9% | 54.5% | ||
| Q3 24 | 2.3% | -1051.6% | ||
| Q2 24 | 5.3% | -3068.0% | ||
| Q1 24 | 4.2% | — |
| Q4 25 | 10.2% | -147.1% | ||
| Q3 25 | 12.0% | -157.4% | ||
| Q2 25 | 132.8% | -285.6% | ||
| Q1 25 | 0.3% | -425.7% | ||
| Q4 24 | 3.0% | 57.7% | ||
| Q3 24 | 3.0% | -925.0% | ||
| Q2 24 | 6.7% | -2503.2% | ||
| Q1 24 | 6.7% | — |
| Q4 25 | $0.08 | $-0.41 | ||
| Q3 25 | $0.10 | $-0.52 | ||
| Q2 25 | $1.09 | $-0.46 | ||
| Q1 25 | $0.00 | $-0.35 | ||
| Q4 24 | $0.02 | $0.52 | ||
| Q3 24 | $0.02 | $-0.20 | ||
| Q2 24 | $0.05 | $-0.13 | ||
| Q1 24 | $0.05 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $83.1M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $88.8M | $114.3M |
| Total Assets | $146.8M | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.1M | $245.0M | ||
| Q3 25 | $70.9M | $288.2M | ||
| Q2 25 | $62.9M | $240.1M | ||
| Q1 25 | $68.7M | $275.7M | ||
| Q4 24 | $70.5M | $314.0M | ||
| Q3 24 | $67.2M | $204.6M | ||
| Q2 24 | $70.0M | $218.7M | ||
| Q1 24 | $83.0M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $88.8M | $114.3M | ||
| Q3 25 | $83.5M | $147.7M | ||
| Q2 25 | $80.7M | $192.3M | ||
| Q1 25 | $51.6M | $229.0M | ||
| Q4 24 | $55.3M | $256.8M | ||
| Q3 24 | $55.7M | $201.0M | ||
| Q2 24 | $58.5M | $215.2M | ||
| Q1 24 | $63.9M | $223.9M |
| Q4 25 | $146.8M | $327.7M | ||
| Q3 25 | $144.6M | $372.8M | ||
| Q2 25 | $148.0M | $313.5M | ||
| Q1 25 | $106.2M | $327.3M | ||
| Q4 24 | $111.3M | $351.2M | ||
| Q3 24 | $114.9M | $217.6M | ||
| Q2 24 | $127.9M | $222.0M | ||
| Q1 24 | $120.3M | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.1M | $-43.5M |
| Free Cash FlowOCF − Capex | $9.9M | — |
| FCF MarginFCF / Revenue | 43.0% | — |
| Capex IntensityCapex / Revenue | 1.0% | 0.0% |
| Cash ConversionOCF / Net Profit | 4.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | $17.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.1M | $-43.5M | ||
| Q3 25 | $10.4M | $-47.0M | ||
| Q2 25 | $-4.3M | $-39.6M | ||
| Q1 25 | $2.2M | $-40.7M | ||
| Q4 24 | $6.4M | $42.0M | ||
| Q3 24 | $954.0K | $-14.5M | ||
| Q2 24 | $-5.1M | $-7.3M | ||
| Q1 24 | $1.7M | $-6.7M |
| Q4 25 | $9.9M | — | ||
| Q3 25 | $10.2M | $-47.2M | ||
| Q2 25 | $-4.5M | $-39.6M | ||
| Q1 25 | $2.1M | $-40.8M | ||
| Q4 24 | $6.3M | $41.7M | ||
| Q3 24 | $845.0K | $-14.6M | ||
| Q2 24 | $-5.2M | $-7.3M | ||
| Q1 24 | $1.7M | $-6.8M |
| Q4 25 | 43.0% | — | ||
| Q3 25 | 43.4% | -145.4% | ||
| Q2 25 | -19.5% | -252.2% | ||
| Q1 25 | 10.0% | -512.1% | ||
| Q4 24 | 28.1% | 48.2% | ||
| Q3 24 | 3.9% | -706.3% | ||
| Q2 24 | -23.0% | -1463.4% | ||
| Q1 24 | 7.8% | — |
| Q4 25 | 1.0% | 0.0% | ||
| Q3 25 | 1.0% | 0.6% | ||
| Q2 25 | 0.9% | 0.3% | ||
| Q1 25 | 0.5% | 1.1% | ||
| Q4 24 | 0.6% | 0.3% | ||
| Q3 24 | 0.5% | 6.8% | ||
| Q2 24 | 0.2% | 7.6% | ||
| Q1 24 | 0.1% | — |
| Q4 25 | 4.33× | — | ||
| Q3 25 | 3.70× | — | ||
| Q2 25 | -0.14× | — | ||
| Q1 25 | 33.48× | — | ||
| Q4 24 | 9.57× | 0.84× | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -3.40× | — | ||
| Q1 24 | 1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EGAN
| Transferred Over Time | $22.0M | 96% |
| Technology Service | $1.2M | 5% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
